SA
CANF logo
Can-Fite BioPharma Ltd.(CANF)
Updated 10:12 AM ETAbout this dataData status
$1.55▲0.13 (9.15%)

Can-Fite BioPharma Ltd. is a biotechnology company focused on developing innovative therapies for cancer and inflammatory diseases, leveraging its proprietary drug candidates such as Namodenoson and CF101. The company operates primarily in Israel and has a growing presence in Europe and the U.S., with clinical trials aimed at addressing significant unmet medical needs.

HealthcareBiotechnologylow - The company has high fixed costs associated with R&D and clinical trials, which limits its operating leverage given the current lack of revenue.

Business Overview

01Licensing agreements with pharmaceutical companies for drug candidates, percentage unknown
02Government and private grants for research and development, percentage unknown

Can-Fite primarily generates revenue through licensing its drug candidates to larger pharmaceutical firms, which provides upfront payments and potential royalties on future sales. The company also seeks funding through grants to support its clinical trials, allowing it to minimize dilution while advancing its pipeline.

What Moves the Stock

Results from clinical trials for key drug candidates like Namodenoson, particularly Phase III outcomes

Partnership announcements or licensing deals with larger pharmaceutical companies

Regulatory approvals or setbacks from health authorities in key markets such as the U.S. and Europe

Market sentiment around the biotechnology sector, influenced by broader healthcare trends

Watch on Earnings
Clinical trial progress updatesPartnership and licensing revenue potentialCash burn rate and funding status

Risk Factors

Regulatory changes affecting drug approval processes

Technological disruption in drug development methodologies

Intense competition from other biotech firms with similar drug candidates

Potential for larger pharmaceutical companies to develop alternative therapies

High cash burn rate due to ongoing clinical trials and R&D expenses

Dependence on external funding sources for operational sustainability

StructuralCompetitiveBalance Sheet

Macro Sensitivity

Economic Cycle

low - The biotechnology sector is less sensitive to economic cycles as it primarily relies on R&D funding and regulatory approvals rather than consumer spending.

Interest Rates

Interest rates affect Can-Fite's financing costs for R&D projects, but given its low debt levels, the impact is minimal. However, higher rates could dampen investor sentiment towards speculative biotech stocks, affecting valuation multiples.

Credit

minimal - The company has a low debt-to-equity ratio, indicating limited reliance on credit markets.

Live Conditions
S&P 500 FuturesRussell 2000 FuturesDow Jones Futures

Profile

growth - Investors looking for high-risk, high-reward opportunities in the biotech sector.

high - The stock has exhibited significant volatility, evidenced by an 85.2% decline over the past year.

Key Metrics to Watch
Clinical trial enrollment rates
Cash runway based on current burn rate
Partnership announcements with larger pharmaceutical companies
Regulatory approval timelines for drug candidates
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.